araag2/HINT huggingface dataset:
Clinical trial NCT01075659 (phase 2, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: nicotine, nicotine, nicotine
SMILES: CC(=O)NC1=CC=C(O)C=C1, CC(=O)NC1=CC=C(O)C=C1, CC(=O)NC1=CC=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy smokers, smoking at least 10 cigarettes daily during at least one year
             preceding inclusion, and smoking within 30 minutes of waking up.

          -  Female participants of child-bearing potential are required to use a medically
             acceptable means of birth control.

          -  A personally signed and dated informed consent document, indicating that the subject
             has been informed of all pertinent aspects of the study.

        Exclusion Criteria:

          -  Pregnancy, lactation or intended pregnancy.

          -  Use of NRT, bupropion, or varenicline, or history of a quit attempt later than 3
             months before screening visit.

          -  Treatment with an investigational product, other than those described in the protocol,
             between 1 month preceding the first treatment visit and the last treatment visit of
             the study.

          -  Prior regular use of any of the investigational products.
Clinical trial NCT00066092 (phase 2, status: completed)
Conditions: lymphoma, hodgkin's lymphoma, non-hodgkin's lymphoma, hematology, oncology
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pegfilgrastim 12 mg, filgrastim, pegfilgrastim 6 mg
SMILES: CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1, N[C@@H](CCCNC(N)=N)C(O)=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
Eligibility criteria:

        -  Hodgkin's or non-Hodgkin's lymphoma patients suitable for an autologous PBPC
             transplant - No previous bone marrow or PBPC transplant
Clinical trial NCT01082640 (phase 2, status: completed)
Conditions: renal impairment
ICD codes: M10.38, M10.30, M10.311, M10.312, M10.319, M10.321, M10.322
Drugs: febuxostat, placebo
SMILES: CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have a serum urate greater than 7 mg/dL and a serum creatinine greater than or
             equal to 1.5 mg at Day -21

          -  Must have a history or presence of gout defined as having one or more of the American
             Rheumatism Association criteria for the diagnosis of gout (the criteria related to
             tophi have been excluded for the purpose of the study)

          -  Must have an estimated Glomerular Filtration Rate (eGFR) of 15 or greater, or less
             than or equal to 50 mL/min, AND a serum creatinine greater than 1.5 mg/dL at Screening
             Visit Day -21

        Exclusion Criteria:

          -  Has secondary hyperuricemia (eg, due to myeloproliferative disorder, or organ
             transplant)

          -  Has tophaceous gout

          -  Has a history of xanthinuria

          -  Has received aspirin greater than 325 mg/day within 35 days prior to Day
             1/Randomization Visit

          -  Has known hypersensitivity or allergy to allopurinol or any component in its
             formulation

          -  Has known hypersensitivity to febuxostat or colchicine or any components in their
             formulation

          -  Has myocardial infarction or stroke within the 90 days prior to the Screening Visit

          -  Has alanine aminotransferase and/or aspartate aminotransferase values greater than 2.0
             times the upper limit of normal

          -  Has end stage renal disease or is likely to be a candidate for dialysis over the 1
             year study period

          -  Has a serum creatinine less than or equal to 1.5 mg/dL, or an estimated Glomerular
             Filtration Rate at Day -21 Screening Visit less than 15 mL/min or greater than 50
             mL/min as calculated by the central laboratory

          -  Is required to take excluded medications
Clinical trial NCT00141492 (phase 2, status: completed)
Conditions: type 2 diabetes, hypogonadism
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: androgel (testosterone gel)
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          1. Able to read and write

          2. Males

          3. Between 30-80 years old

          4. Have type 2 diabetes

          5. Diagnoses of hypogonadism or low testosterone

        Exclusion Criteria:

          1. On insulin monotherapy

          2. Use of testosterone therapy within the last 6 months

          3. Male breast cancer

          4. History of prostate cancer

          5. History of clinically significant sleep apnea
Clinical trial NCT00708214 (phase 2, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bibw 2992, bibw 2992, letrozole, letrozole
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
Eligibility criteria:

        Inclusion criteria:

          -  Female patients with histologically proven breast adenocarcinoma

          -  Presence of metastatic disease No more than 2 prior chemotherapy regimens for
             metastatic disease, which could include trastuzumab Patients must currently be on
             letrozole and developed acquired resistance as defined by disease progression on
             letrozole following previous response (partial response or better, stable disease
             superior or equal to 24 weeks)

        Diagnosis of disease progression inferior or equal to 6 weeks prior to trial entrydefined
        as:

          1. Increase in the number of bone lesions on bone scan or on MRI AND/OR

          2. Increased pain in an area of known bony metastasis AND superior or equal to 2 serial
             elevations in CA 15.3 AND/OR

          3. Progression according to RECIST criteria on CT scan, MRI, or x-ray Patients must have
             documented menopause confirmed by estradiol level inferior to 11 pg/ml

        Exclusion criteria:

          -  Premenopausal patients

          -  Rapidly progressive disease in major organs (i.e. lymphangitic spread in the lung
             and/or bulky liver metastasis) Patient with brain metastasis Significant
             cardiovascular diseases Previous treatment with an EGFR and/or HER-2 inhibiting
             drug(patients who received trastuzumab with chemotherapy but not with letrozole can be
             enrolled)
Clinical trial NCT00486044 (phase 2, status: completed)
Conditions: alzheimer disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: simvastatin, placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 35 to 69

          -  Parent with Alzheimer's disease

        Exclusion Criteria:

          -  Current use of cholesterol-lowering medication

          -  Active liver disease

          -  History of adverse reaction to statins

          -  Contraindication to lumbar puncture

          -  Elevated lab values (creatine kinase and creatinine)

          -  Use of medications known to interact with statins

          -  History of dementia

          -  Currently pregnant or planning to become pregnant

          -  Use of large quantities of grapefruit juice (more than 1 quart per day)

          -  Current involvement in another investigational drug study

          -  Contraindications to MRI (for MRI sub-study)

          -  Ethical contraindication to placebo (persons with high vascular risk)
Clinical trial NCT00631007 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: int131 besylate, pioglitazone hcl, placebo
SMILES: CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Type 2 diabetes and on either sulfonylurea monotherapy or sulfonylurea
             plus metformin combination therapy for at least 3 months at stable dose

          -  Males and Females (of non-childbearing potential or who are using dual barrier methods
             of contraception) between 30 and 75 years of age

          -  HbA1c must be ≥7.5% and ≤10% at screening

          -  Fasting Plasma Glucose must be <240 mg/dL at screening

        Exclusion Criteria:

          -  History of type 1 diabetes

          -  History of diabetic ketoacidosis

          -  NYHA Class III or IV cardiac status or hospitalization for congestive heart failure
             within 6 weeks prior to Visit 1

          -  Treatment with any non-peroxisome proliferator-activated receptor (non-PPAR)
             antidiabetic agent, investigational or approved, other than metformin or permitted
             sulfonylureas within 3 months prior to screening

          -  Treatment with rosiglitazone, pioglitazone, or any PPAR investigational antidiabetic
             agent within 6 month prior to screening

          -  Body mass index >45 kg/m2

          -  Fasting triglycerides >500 mg/dL

          -  Uncontrolled hypertension (sitting systolic blood pressure >160 mmHg and/or sitting
             diastolic blood pressure >100 mmHg

          -  Presence of diabetic complications, which in the opinion of the investigator, would
             complicate the subject's participation in the study (i.e., require initiation of new
             medication)
Clinical trial NCT00544960 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: at-101 and docetaxel, placebo and docetaxel
SMILES: [H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H], [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed Stage IIIb with pleural/pericardial effusion
             or Stage IV non-small cell lung cancer (NSCLC).

          -  Progression of disease after one prior systemic chemotherapeutic regimen for locally
             advanced or metastatic NSCLC. (Systemic therapies given in the adjuvant setting are
             counted only if the patient relapses within 6 months of the last cycle of therapy.) In
             addition to the one prior chemotherapeutic regimen, patients may have received
             erlotinib in any setting.

          -  All patients must have measurable disease.

          -  No unstable or progressive brain metastases.

          -  Patients may have received prior radiation therapy but they must have recovered from
             all treatment-related toxicities.

          -  ECOG performance status 0-1

          -  Adequate hematologic function

          -  Adequate liver and renal function

          -  Ability to swallow oral medication

        Exclusion Criteria:

          -  Prior chemotherapy regimen containing docetaxel.

          -  Active secondary malignancy.

          -  Uncontrolled concurrent illness including, but not limited to: serious uncontrolled
             infection, symptomatic congestive heart failure (CHF), unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with the study requirements.

          -  Failure to recover from toxicities related to prior therapy (e.g., surgery, radiation,
             chemotherapy).
Clinical trial NCT01581918 (phase 2, status: unknown status)
Conditions: chemotherapy-induced nausea and vomiting
ICD codes: D61.810
Drugs: carbamazepine
SMILES: NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  older than 18 years old

          -  starting moderate or highly emetogenic chemotherapy defined as containing
             cisplatin,doxorrubicin or epirrubicin in higher doses than 60mg/m2, 50mg/m2 e 50mg/m2
             respectively

          -  they must sign in the informed consent form.

        Exclusion Criteria:

          -  previuos chemotherapy

          -  low emetogenic antiemetic potential

          -  disagree and don't sign in the consent form.
Clinical trial NCT01288716 (phase 2, status: completed)
Conditions: autism spectrum disorders
ICD codes: Z16.12
Drugs: arbaclofen
SMILES: [H][C@@](CN)(CC(O)=O)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Autism Spectrum Disorders (ASD)

          -  Current pharmacological treatment regimen has been stable for at least 4 weeks prior
             to Screening.

          -  Subjects with a history of seizure disorder must currently be receiving treatment with
             antiepileptics and must have been seizure free for 6 months, or must be seizure free
             for 3 years if not currently receiving antiepileptics.

          -  If the subject is already receiving stable non-pharmacologic educational, behavioral,
             and/or dietary interventions, participation in these programs must have been
             continuous during the 2 months prior to Screening

        Exclusion Criteria:

          -  Subjects with any condition, including alcohol and drug abuse, which might interfere
             with the conduct of the study, confound interpretation of the study results, or
             endanger their own well-being.

          -  Subjects who plan to initiate or change pharmacologic or non-pharmacologic
             interventions during the course of the study.

          -  Subjects who have taken another investigational drug within the last 30 days.

          -  Subjects who are not able to take oral medications
Clinical trial NCT01516957 (phase 2, status: terminated)
Conditions: psoriatic arthritis
ICD codes: L40.52
Drugs: amg 827 140, placebo, amg 827 280, amg 827 210
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    sponsor decision
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has had a diagnosis of psoriatic arthritis (by the Classification of Psoriatic
             Arthritis (CASPAR) criteria) for at least 6 months

          -  Subject has ≥ 3 tender and ≥ 3 swollen joints

        Exclusion Criteria:

          -  Subject has an active infection or history of infections (systemic anti-infectives
             were used within 28 days; requiring hospitalization or intravenous anti-infectives
             within 8 weeks; recurrent or chronic)

          -  Significant concurrent medical conditions

          -  Pregnant or breast feeding

          -  Significant Laboratory abnormalities

          -  Use of sulfasalazine, hydroxychloroquine, systemically administered calcineurin
             inhibitors, azathioprine, parenteral corticosteroids including intramuscular or
             intraarticular administration, or live vaccines within 28 days

          -  Use of anti-TNF therapy within 2 months

          -  Use of an anti-interleukin (IL)12/IL-23 drug or other experimental or commercially
             available biologic therapies for psoriasis and/or psoriatic arthritis within 3 months

          -  Prior use of rituximab

          -  Prior use of anti-IL-17 biologic therapy, including AMG 827
Clinical trial NCT01257607 (phase 2, status: completed)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: mim-d3 ophthalmic solution, placebo ophthalmic solution
SMILES: NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)C2=C(OCC[C@H](NC1=O)C(=O)NCC(O)=O)C=CC(=C2)[N+]([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Be at least 18 years of age

          2. Provide written informed consent

          3. Have a reported history of dry eye

          4. Have a history of use or desire to use eye drops for dry eye

        Exclusion Criteria:

          1. Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active
             ocular inflammation (e.g. follicular conjunctivitis) at Visit 1, or have been
             diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or
             conjunctiva, within the last 12 months

          2. Have any planned ocular and/or lid surgeries over the study period

          3. Have corrected visual acuity greater than or equal to +0.7 as assessed by Early
             Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1

          4. Have an uncontrolled systemic disease

          5. Be a woman who is pregnant, nursing or planning a pregnancy

          6. Be a woman of childbearing potential who is not using an acceptable means of birth
             control; acceptable methods of contraception include: hormonal - oral, implantable,
             injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with
             a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner.
             For non-sexually active females, abstinence may be regarded as an adequate method of
             birth control; however, if the subject becomes sexually active during the study, she
             must agree to use adequate birth control as defined above for the remainder of the
             study

          7. Have a known allergy and/or sensitivity to the test article or its components

          8. Have a condition or be in a situation which the investigator feels may put the subject
             at significant risk, may confound the study results, or may interfere significantly
             with the subject's participation in the study

          9. Be currently enrolled in an investigational drug or device study or have used an
             investigational drug or device within 45 days of Visit 1

         10. Be unable or unwilling to follow instructions, including participation in all study
             assessments and visits
Clinical trial NCT00698204 (phase 2, status: completed)
Conditions: oral mucositis
ICD codes: K12.30, K12.39, K12.33, K12.31, K12.32
Drugs: celecoxib, placebo
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Patients who will be receiving at least 5000 centigray (cGy) radiation therapy to at
             least 2 of 14 pre-defined areas in the oral cavity.

          -  Women of childbearing potential must agree to use a medically accepted form of
             contraception during the course of the study. Women of childbearing potential must
             have a documented negative pregnancy test within fourteen days of enrollment in the
             study.

          -  Patient's willing and able to provide written informed consent for the study.

        Key Exclusion Criteria:

          -  Patients with known hypersensitivity to celecoxib or other COX-2 inhibitors.

          -  Patients who have experienced asthma, urticaria, or allergic-type reactions after
             taking salicylates (e.g. aspirin) or Non-steroidal anti-inflammatory drugs (NSAIDs).

          -  Patients who have demonstrated allergic-type reactions to sulfonamides.

          -  Patients with a history of gastric, esophageal, pyloric channel or duodenal ulcer
             disease or gastrointestinal bleeding.

          -  Patients with a history of inflammatory bowel disease (e.g. Crohn's disease,
             ulcerative colitis) or pancreatic disease.

          -  Patients with severe hepatic impairment.

          -  Patients with advanced renal disease.

          -  Patients with a significant bleeding disorder.

          -  Patients under the age of 18 or over the age of 75.

          -  Women who are pregnant or nursing.

          -  Patients with a history of thromboembolic events including myocardial infarction,
             pulmonary embolism, deep venous thrombosis, transient ischemic attack and ischemic
             cerebrovascular accident (stroke).

          -  Patients who have had coronary angioplasty, coronary artery bypass surgery or another
             cardiac revascularization procedure.

          -  Patients with a history of a cardiac arrhythmia requiring anti-arrhythmic therapy,
             angina pectoris or congestive heart failure.
Clinical trial NCT00281827 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, gemcitabine hydrochloride, thalidomide
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Reason stopped: 
    due to drug unavailability
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC),
             including any of the following histologic subtypes:

               -  Squamous cell carcinoma

               -  Adenocarcinoma

               -  Large cell undifferentiated carcinoma

          -  Stage II or IIIA disease

          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
             conventional techniques OR ≥ 10 mm by spiral Computerized Axial Tomography (CT) scan

          -  No tumor involving the superior sulcus (e.g., Pancoast tumor)

          -  Karnofsky performance status 70-100%

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Creatinine ≤ 2 mg/dL

          -  Bilirubin < 2 mg/dL

          -  Aspartate aminotransferase (AST) < 3 times upper limit of normal

        Exclusion Criteria:

          -  Pregnant or nursing

               -  No nursing during and for ≥ 4 weeks after completion of study treatment

          -  Positive pregnancy test

          -  Fertile female patients must use 2 effective methods of contraception 4 weeks before,
             during, and for 4 weeks after completion of study treatment

          -  Fertile male patients must use effective barrier contraception during and for 4 weeks
             after completion of study treatment

          -  Blood, sperm, or ova donation during study treatment

          -  Post obstructive pneumonia

          -  Other serious infection or medical illness that would preclude study participation

          -  Other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix, or other malignancy that
             is unlikely to affect survival for the next 3 years

          -  Less than 5 years since prior resection of lung disease

          -  Prior systemic chemotherapy or radiotherapy for non-small cell lung cancer (NSCLC)

          -  Other concurrent chemotherapy or radiotherapy

          -  Concurrent hormonal therapy or immunotherapy

          -  Other concurrent anticancer therapy

          -  Other concurrent investigational agents

          -  Concurrent participation in another clinical study